159 related articles for article (PubMed ID: 27828640)
21. Novel treatment of Sézary-like syndrome due to adult T-cell leukaemia/lymphoma with daclizumab (humanized anti-interleukin-2 receptor alpha antibody).
Osborne GE; Pagliuca A; Ho A; du Vivier AW
Br J Dermatol; 2006 Sep; 155(3):617-20. PubMed ID: 16911291
[TBL] [Abstract][Full Text] [Related]
22. Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome.
Lenihan DJ; Alencar AJ; Yang D; Kurzrock R; Keating MJ; Duvic M
Blood; 2004 Aug; 104(3):655-8. PubMed ID: 15073032
[TBL] [Abstract][Full Text] [Related]
23. Plaques and tumors in a patient with refractory Sézary syndrome treated with mogamulizumab.
Ricci C; Pileri A; Agostinelli C; Ambrosi F; Zinzani PL; Sabattini E
J Dtsch Dermatol Ges; 2018 Oct; 16(10):1263-1265. PubMed ID: 30277017
[No Abstract] [Full Text] [Related]
24. Alemtuzumab as first- and second-line treatment in patients with Sézary syndrome-The experience of a tertiary centre.
Nogueira M; Lau C; Teixeira MDA; Peixeiro R; Cabral R; Fernandes I
J Eur Acad Dermatol Venereol; 2024 Jan; 38(1):e86-e88. PubMed ID: 37595960
[No Abstract] [Full Text] [Related]
25. Subcutaneous alemtuzumab for Sézary Syndrome in the very elderly.
Alinari L; Geskin L; Grady T; Baiocchi RA; Bechtel MA; Porcu P
Leuk Res; 2008 Aug; 32(8):1299-303. PubMed ID: 18096224
[TBL] [Abstract][Full Text] [Related]
26. Sézary syndrome managed with histone deacetylase inhibitor followed by anti-CCR4 monoclonal antibody.
Numata T; Nagatani T; Shirai K; Maeda T; Mae K; Nakasu M; Saito M; Usuda T; Tsuboi R; Okubo Y
Clin Exp Dermatol; 2018 Apr; 43(3):281-285. PubMed ID: 29327377
[TBL] [Abstract][Full Text] [Related]
27. Immunophenotypic stability of Sézary cells by flow cytometry: usefulness of flow cytometry in assessing response to and guiding alemtuzumab therapy.
Vaughan J; Harrington AM; Hari PN; Kroft SH; Olteanu H
Am J Clin Pathol; 2012 Mar; 137(3):403-11. PubMed ID: 22338052
[TBL] [Abstract][Full Text] [Related]
28. Fatal adenoviral and enteroviral infections and an Epstein-Barr virus positive large B-cell lymphoma after alemtuzumab treatment in a patient with refractory Sézary syndrome.
Roch N; Salameire D; Gressin R; Morand P; Epaulard O; Pavese P; Brion JP; Stahl JP
Scand J Infect Dis; 2008; 40(4):343-6. PubMed ID: 17934981
[TBL] [Abstract][Full Text] [Related]
29. Successful treatment of refractory Sezary syndrome by anti-PD-1 antibody (nivolumab).
Shen K; Liu Y; Cao X; Zhou D; Li J
Ann Hematol; 2017 Apr; 96(4):687-688. PubMed ID: 28120019
[No Abstract] [Full Text] [Related]
30. Brentuximab-induced splinter nail haemorrhages in a patient with Sézary syndrome: A case report.
Filipovic N; Likic R; Bulat V; Gašparov S; Delas Azdajic M
Br J Clin Pharmacol; 2022 Aug; 88(8):3883-3886. PubMed ID: 35088431
[TBL] [Abstract][Full Text] [Related]
31. The emergence of Sézary cells during the treatment of cutaneous T-cell lymphoma.
Sato M; Ishikawa O; Miyachi Y
Br J Dermatol; 1995 Nov; 133(5):810-3. PubMed ID: 8555042
[TBL] [Abstract][Full Text] [Related]
32. Serum chemokine levels differentially regulated by vorinostat in a Sézary syndrome patient.
Miyagaki T; Sugaya M; Oka T; Fujita H; Sato S
Br J Dermatol; 2015 Aug; 173(2):620-2. PubMed ID: 25640919
[No Abstract] [Full Text] [Related]
33. Reduction of regulatory T cells by Mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive/refractory mycosis fungoides and Sézary syndrome.
Ni X; Jorgensen JL; Goswami M; Challagundla P; Decker WK; Kim YH; Duvic MA
Clin Cancer Res; 2015 Jan; 21(2):274-85. PubMed ID: 25376389
[TBL] [Abstract][Full Text] [Related]
34. Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas.
de Masson A; Guitera P; Brice P; Moulonguet I; Mouly F; Bouaziz JD; Battistella M; Madelaine I; Roux J; Ram-Wolff C; Cayuela JM; Bachelez H; Bensussan A; Michel L; Bagot M
Br J Dermatol; 2014 Mar; 170(3):720-4. PubMed ID: 24438061
[TBL] [Abstract][Full Text] [Related]
35. Mogamulizumab-induced vitiligo in patients with Sézary syndrome: three cases.
Algarni AS; Ram-Wolff C; Bagot M; De Masson A
Eur J Dermatol; 2021 Apr; 31(2):213-216. PubMed ID: 33814357
[TBL] [Abstract][Full Text] [Related]
36. [The Sézary syndrome].
Ferreira F; Correia TM; Callabro L; Andrade J
Acta Med Port; 1998 Dec; 11(12):1135-9. PubMed ID: 10192992
[TBL] [Abstract][Full Text] [Related]
37. Administration of alemtuzumab and G-CSF to adults with relapsed or refractory acute lymphoblastic leukemia: results of a phase II study.
Gorin NC; Isnard F; Garderet L; Ikhlef S; Corm S; Quesnel B; Legrand O; Cachanado M; Rousseau A; Laporte JP
Eur J Haematol; 2013 Oct; 91(4):315-21. PubMed ID: 23738686
[TBL] [Abstract][Full Text] [Related]
38. Sézary Syndrome Presenting With Renal Involvement.
Wickenden K; Graham-Brown MPM; Veitch D; Dormer J; Bamford M; Graham-Brown RAC; Warwick G; Wagner S; Burton JO
Am J Kidney Dis; 2018 Dec; 72(6):890-894. PubMed ID: 29941220
[TBL] [Abstract][Full Text] [Related]
39. A case of refractory Sézary syndrome with large-cell transformation responsive to brentuximab vedotin.
Corey K; Cook D; Bekker J; Mugnaini E; Lin JH
JAMA Dermatol; 2014 Feb; 150(2):210-2. PubMed ID: 24352253
[No Abstract] [Full Text] [Related]
40. A case of bullous Sézary syndrome.
Ono A; Isomura I; Isogai Z; Shintani Y; Suzuki A; Morita A
J Dermatol; 2004 Dec; 31(12):1027-31. PubMed ID: 15801270
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]